BioCentury | Apr 6, 2021
Finance

VCs led by HBM, Samsara back single-asset Mitsubishi Tanabe spinout Mineralys with $40M for hypertension program

...Co. Ltd. (Tokyo:4502); and Exalys Therapeutics Inc., which is developing PTGER4 antagonists under a license from Eisai Co. Ltd....
BioCentury | Mar 23, 2021
Management Tracks

Brainard to succeed Hallal as AlloVir CEO; plus Illumina, NeoGenomics, Nordic Nanovector, Abeona, Delix and more

...Abeona last year, before which he held various senior executive positions at Kite Pharma Inc., Eisai Co. Ltd....
BioCentury | Mar 20, 2021
Product Development

March 19 Quick Takes: Ovarian readout for Rubraca lifts Clovis shares; plus Keytruda-Lenvima combo meets in endometrial, approvals for Kiniksa, J&J and more

...cancer endpointsIn another SGO presentation, Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) plus Lenvima lenvatinib from Eisai Co. Ltd....
BioCentury | Mar 19, 2021
Product Development

Pandemic response ushers in new era of biopharma data sharing: Guest Commentary

...Inc., Alnylam Pharmaceuticals Inc., Arbutus Biopharma Corp., AstraZeneca plc, Bayer AG, Bristol Myers Squibb Co., Eisai Co. Ltd....
BioCentury | Mar 16, 2021
Product Development

The clinical pipeline for Alzheimer’s disease: Data Byte

...of tau pathology in the brain. Ongoing studies of other amyloid mAbs from Roche (SIX:ROG; OTCQX:RHHBY), Eisai Co. Ltd....
...BIIB037) ALZ-801, blu8499, NRM8499, NRM-8499 Posiphen varoglutamstat (PQ912) Semorinemab, RG6100 ABBV-8E12, C2N-8E12 gosuranemab, BIIB092, bms-986168, ipn007 zagotenemab, LY3303560 AL003 AL002 AR1001 BPN14770 AMX0035 Simufilam, sumifilam (PTI-125) Eli Lilly and Co. Eisai Co. Ltd. Biogen...
BioCentury | Mar 3, 2021
Product Development

Verdine’s FogPharma to bring lead cell-permeable peptide into clinic with $107M series C

...Phase IIa testing to treat desmoid tumors; and Eisai Co. Ltd....
BioCentury | Feb 20, 2021
Management Tracks

Biden nominates Brooks-LaSure to lead CMS; plus moves at Everest, Abbisko, NovalGen, Acorda, SVB Capital and Avoro Ventures

...officer. Guo previously served as VP and deputy global brand lead for Lenvima lenvatinib at Eisai Co. Ltd....
...in the biopharma practice at New Enterprise Associates. BC Staff Everest Medicines Ltd. Abbisko Therapeutics Co. Ltd. Acorda Therapeutics Inc. Eisai Co. Ltd. LianBio Pfizer...
BioCentury | Feb 20, 2021
Product Development

Snapshot of Phase III therapies for Alzheimer’s disease: Data Byte

...its June 7 PDUFA date. That leaves lecanemab from Eisai Co. Ltd....
BioCentury | Feb 10, 2021
Product Development

First-line RCC immunotherapy combinations shine at ASCO GU

...pembrolizumb plus VEGFR inhibitor Lenvima lenvatinib from Eisai Co. Ltd....
...Kisplyx, lenvatinib mesylate (E7080, MK-7902) Merck & Co. Inc. Eisai Co. Ltd. Bristol...
BioCentury | Feb 4, 2021
Deals

Feb. 3 Quick Takes: Hillhouse takes stakes in InnoCare, Luye; plus Merck KGaA, Inivata, Reverie, Neurocrine, Eisai and more

...the Eisai Innovation Center BioLab, an incubator for companies focused on neurological diseases, within the Eisai...
...and regulatory milestones, plus royalties. BC Staff Tepmetko (tepotinib, MSC2156119J) Hillhouse Capital Merck KGaA Reverie Labs Inc. Neurocrine Biosciences Inc. InnoCare Pharma Ltd. Eisai Co. Ltd. Genentech...
Items per page:
1 - 10 of 1874
BioCentury | Apr 6, 2021
Finance

VCs led by HBM, Samsara back single-asset Mitsubishi Tanabe spinout Mineralys with $40M for hypertension program

...Co. Ltd. (Tokyo:4502); and Exalys Therapeutics Inc., which is developing PTGER4 antagonists under a license from Eisai Co. Ltd....
BioCentury | Mar 23, 2021
Management Tracks

Brainard to succeed Hallal as AlloVir CEO; plus Illumina, NeoGenomics, Nordic Nanovector, Abeona, Delix and more

...Abeona last year, before which he held various senior executive positions at Kite Pharma Inc., Eisai Co. Ltd....
BioCentury | Mar 20, 2021
Product Development

March 19 Quick Takes: Ovarian readout for Rubraca lifts Clovis shares; plus Keytruda-Lenvima combo meets in endometrial, approvals for Kiniksa, J&J and more

...cancer endpointsIn another SGO presentation, Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) plus Lenvima lenvatinib from Eisai Co. Ltd....
BioCentury | Mar 19, 2021
Product Development

Pandemic response ushers in new era of biopharma data sharing: Guest Commentary

...Inc., Alnylam Pharmaceuticals Inc., Arbutus Biopharma Corp., AstraZeneca plc, Bayer AG, Bristol Myers Squibb Co., Eisai Co. Ltd....
BioCentury | Mar 16, 2021
Product Development

The clinical pipeline for Alzheimer’s disease: Data Byte

...of tau pathology in the brain. Ongoing studies of other amyloid mAbs from Roche (SIX:ROG; OTCQX:RHHBY), Eisai Co. Ltd....
...BIIB037) ALZ-801, blu8499, NRM8499, NRM-8499 Posiphen varoglutamstat (PQ912) Semorinemab, RG6100 ABBV-8E12, C2N-8E12 gosuranemab, BIIB092, bms-986168, ipn007 zagotenemab, LY3303560 AL003 AL002 AR1001 BPN14770 AMX0035 Simufilam, sumifilam (PTI-125) Eli Lilly and Co. Eisai Co. Ltd. Biogen...
BioCentury | Mar 3, 2021
Product Development

Verdine’s FogPharma to bring lead cell-permeable peptide into clinic with $107M series C

...Phase IIa testing to treat desmoid tumors; and Eisai Co. Ltd....
BioCentury | Feb 20, 2021
Management Tracks

Biden nominates Brooks-LaSure to lead CMS; plus moves at Everest, Abbisko, NovalGen, Acorda, SVB Capital and Avoro Ventures

...officer. Guo previously served as VP and deputy global brand lead for Lenvima lenvatinib at Eisai Co. Ltd....
...in the biopharma practice at New Enterprise Associates. BC Staff Everest Medicines Ltd. Abbisko Therapeutics Co. Ltd. Acorda Therapeutics Inc. Eisai Co. Ltd. LianBio Pfizer...
BioCentury | Feb 20, 2021
Product Development

Snapshot of Phase III therapies for Alzheimer’s disease: Data Byte

...its June 7 PDUFA date. That leaves lecanemab from Eisai Co. Ltd....
BioCentury | Feb 10, 2021
Product Development

First-line RCC immunotherapy combinations shine at ASCO GU

...pembrolizumb plus VEGFR inhibitor Lenvima lenvatinib from Eisai Co. Ltd....
...Kisplyx, lenvatinib mesylate (E7080, MK-7902) Merck & Co. Inc. Eisai Co. Ltd. Bristol...
BioCentury | Feb 4, 2021
Deals

Feb. 3 Quick Takes: Hillhouse takes stakes in InnoCare, Luye; plus Merck KGaA, Inivata, Reverie, Neurocrine, Eisai and more

...the Eisai Innovation Center BioLab, an incubator for companies focused on neurological diseases, within the Eisai...
...and regulatory milestones, plus royalties. BC Staff Tepmetko (tepotinib, MSC2156119J) Hillhouse Capital Merck KGaA Reverie Labs Inc. Neurocrine Biosciences Inc. InnoCare Pharma Ltd. Eisai Co. Ltd. Genentech...
Items per page:
1 - 10 of 1874